E. Ohman J or Asset Management AB Increases Stock Position in RadNet, Inc. $RDNT

Key Points

• Institutional ownership increased: E. Ohman J or Asset Management AB boosted its RadNet stake by 1,144.3% to 452,966 shares, while institutional investors collectively own 77.9% of the company.
• RadNet delivered strong Q2 results: Revenue rose 25% year over year to $622.7 million, and adjusted EPS of $0.29 exceeded analyst expectations. The company also raised its 2026 revenue, adjusted EBITDA and free-cash-flow guidance.
• Risks remain mixed: CEO Cornelis Wesdorp and a director sold shares, while adjusted EPS and GAAP net income declined year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $87.43.

E. Ohman J or Asset Management AB grew its position in shares of RadNet, Inc. (NASDAQ:RDNT - Free Report) by 1,144.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 452,966 shares of the medical research company's stock after purchasing an additional 416,563 shares during the period. E. Ohman J or Asset Management AB owned approximately 0.58% of RadNet worth $27,934,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in RDNT. RTW Investments LP lifted its position in shares of RadNet by 39.9% in the fourth quarter. RTW Investments LP now owns 3,938,500 shares of the medical research company's stock worth $281,012,000 after buying an additional 1,122,956 shares in the last quarter. Polar Capital Holdings Plc purchased a new position in RadNet during the 3rd quarter valued at approximately $63,423,000. Price T Rowe Associates Inc. MD grew its holdings in RadNet by 30.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,699,082 shares of the medical research company's stock valued at $192,581,000 after buying an additional 627,936 shares in the last quarter. Ameriprise Financial Inc. increased its stake in RadNet by 79.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,394,552 shares of the medical research company's stock worth $79,364,000 after acquiring an additional 618,392 shares during the last quarter. Finally, Defiance ETFs LLC bought a new stake in RadNet in the 4th quarter worth approximately $37,019,000. 77.90% of the stock is owned by institutional investors.

Insider Buying and Selling

In other RadNet news, CEO Cornelis Wesdorp sold 4,750 shares of the firm's stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total value of $276,022.50. Following the completion of the sale, the chief executive officer directly owned 69,075 shares in the company, valued at $4,013,948.25. This trade represents a 6.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David L. Swartz sold 2,699 shares of the firm's stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $53.89, for a total transaction of $145,449.11. Following the completion of the sale, the director owned 177,013 shares of the company's stock, valued at approximately $9,539,230.57. This trade represents a 1.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.14% of the stock is owned by insiders.

Trending Headlines about RadNet

Here are the key news stories impacting RadNet this week:

• Positive Sentiment: Q2 results exceeded expectations: Adjusted earnings per share was $0.29 versus the $0.20 consensus estimate, while revenue rose 25% year over year to a record $622.7 million, above estimates of $610.9 million. RadNet Q2 earnings results
• Positive Sentiment: Strong imaging demand supported growth: Aggregate MRI, CT and PET/CT procedures increased 21.2%, while same-center advanced imaging volume rose 9.6%. Advanced imaging represented 29.9% of total procedures, helping lift the Imaging Center segment’s adjusted EBITDA margin to 16.1%. RadNet second-quarter financial results
• Positive Sentiment: Digital Health momentum accelerated: Segment revenue increased 56.5% to $32.4 million, and annual recurring revenue nearly doubled to $105.5 million. RadNet also cited approximately $21 million in new second-quarter contract value and a recently FDA-cleared breast-ultrasound AI solution. RadNet strong Q2 results
• Positive Sentiment: 2026 outlook was raised: RadNet increased Imaging Center revenue guidance to $2.37 billion-$2.42 billion, adjusted EBITDA guidance to $345 million-$358 million and free-cash-flow guidance to $115 million-$125 million. RadNet Q2 earnings call transcript
• Negative Sentiment: Profitability remained mixed: Adjusted EPS declined from $0.34 a year earlier to $0.29, and GAAP net income attributable to shareholders fell to $7.5 million from $14.5 million. Digital Health adjusted EBITDA also declined 27.2% as RadNet invested in infrastructure, sales and implementation capabilities.

RadNet Trading Up 6.8%

Shares of NASDAQ RDNT opened at $77.28 on Tuesday. RadNet, Inc. has a 1-year low of $50.82 and a 1-year high of $85.84. The business has a fifty day moving average price of $61.44 and a 200 day moving average price of $61.71. The stock has a market capitalization of $6.08 billion, a P/E ratio of -429.31 and a beta of 1.36. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.17 and a quick ratio of 1.17.

RadNet (NASDAQ:RDNT - Get Free Report) last posted its earnings results on Sunday, August 9th. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.10. The company had revenue of $622.72 million for the quarter, compared to analyst estimates of $610.87 million. RadNet had a positive return on equity of 2.77% and a negative net margin of 0.66%.The firm's quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.31 earnings per share. Equities research analysts expect that RadNet, Inc. will post 0.52 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on RDNT. Barclays lowered their target price on RadNet from $70.00 to $65.00 and set an "overweight" rating for the company in a research report on Wednesday, May 20th. Zacks Research downgraded RadNet from a "hold" rating to a "strong sell" rating in a report on Monday, July 13th. Jefferies Financial Group reaffirmed a "buy" rating on shares of RadNet in a research report on Friday, July 31st. Finally, Weiss Ratings downgraded RadNet from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, May 12th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $87.43.

RadNet Profile

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.

Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source